Finance

Lists
Q3 2026 earnings • in 5 days
See details
ALC:NYSE
Alcon AG
$74.67
-2.46%
(-1.88) 1D
Nov 6, 9:55:23 AM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ALC...
Open
$74.24
High
$74.84
Low
$74.01
Mkt. cap
30.51B
Avg. vol.
1.83M
Volume
82.85K
52-wk high
$87.64
52-wk low
$61.84
Beta
0.87
Shares outstanding
483.40M
No. of employees
25K
Open
$74.24
High
$74.84
Low
$74.01
Mkt. cap
30.51B
Avg. vol.
1.83M
Volume
82.85K
52-wk high
$87.64
52-wk low
$61.84
Beta
0.87
Shares outstanding
483.40M
No. of employees
25K
News stories
From web sources and news partners
Profile
Alcon Inc. is a Swiss-American pharmaceutical and medical device company specializing in eye care products. Alcon is incorporated in the Canton of Fribourg, Switzerland, and its global headquarters are located in Geneva, but its main operational base is in Fort Worth, Texas, United States, where it employs about 4,500 people. Alcon was a subsidiary of Novartis until April 2019, when it was spun out into a separate publicly traded company. Alcon itself has a number of subsidiaries, including Aerie Pharmaceuticals, focused on therapies for glaucoma and other diseases of the eye, and WaveLight, which develops and manufactures laser eye surgery technologies. Wikipedia
About Alcon AG
CEODavid J. Endicott
Employees25K
Founded1945
HeadquartersGeneva, Geneva, Switzerland
SectorHealth Care
IndustryMedical device
Websitealcon.com
Analyst
Recommendation
Action
Price target
Projected
Date
No analyst ratings found.
Next call in 5 days
Wed, Nov 11, 3:00 PM
Fiscal period
Q3 2026
- / $0.89
Revenue / Est. (USD)
- / 2.74B
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
2.61B
2.72B
2.71B
2.82B
Cost of goods sold
1.16B
1.20B
1.14B
1.15B
Cost of revenue
1.16B
1.20B
1.14B
1.15B
Research and development expenses
248.00M
273.00M
245.00M
261.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
865.00M
901.00M
882.00M
964.00M
Operating expense
1.12B
1.20B
1.23B
1.26B
Total operating expenses
2.28B
2.40B
2.38B
2.41B
Operating income
336.00M
318.00M
330.00M
413.00M
Other non operating income
3.00M
-28.00M
-
-
EBT including unusual items
283.00M
264.00M
240.00M
-46.00M
EBT excluding unusual items
287.00M
271.00M
278.00M
356.00M
Income tax expense
46.00M
47.00M
51.00M
-46.00M
Effective tax rate
16.25%
17.80%
21.25%
100.00%
Other operating expenses
9.00M
26.00M
106.00M
37.00M
Net income
237.00M
217.00M
189.00M
-
Net profit margin
9.07%
7.98%
6.98%
-
Earnings per share
0.79
0.78
0.85
0.84
Interest and investment income
-
74.00M
2.00M
-
Interest expense
-51.00M
-53.00M
-52.00M
-53.00M
Net interest expenses
-51.00M
21.00M
-50.00M
-53.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
784.00M
441.00M
600.00M
676.00M
Gain or loss from assets sale
5.00M
9.00M
2.00M
2.00M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps